Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) have earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $21.40.

A number of analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 target price on shares of Protara Therapeutics in a research note on Tuesday, February 10th. Piper Sandler began coverage on shares of Protara Therapeutics in a research report on Wednesday, January 7th. They set an “overweight” rating and a $24.00 price target on the stock. TD Cowen reissued a “buy” rating on shares of Protara Therapeutics in a report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a research report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. initiated coverage on shares of Protara Therapeutics in a research note on Wednesday, March 4th. They set an “overweight” rating and a $27.00 target price on the stock.

Protara Therapeutics Price Performance

TARA stock opened at $5.26 on Friday. Protara Therapeutics has a 1 year low of $2.77 and a 1 year high of $7.82. The firm has a market capitalization of $271.57 million, a PE ratio of -3.98 and a beta of 1.40. The business has a 50 day simple moving average of $6.10 and a 200-day simple moving average of $5.37.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings data on Tuesday, March 10th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). On average, equities research analysts expect that Protara Therapeutics will post -3.32 EPS for the current year.

Key Protara Therapeutics News

Here are the key news stories impacting Protara Therapeutics this week:

• Positive Sentiment: Lifesci Capital raised its 2026 outlook across the board — boosting Q1 to ($0.34) from ($0.38), Q2 to ($0.37) from ($0.41), Q3 to ($0.39) from ($0.44), Q4 to ($0.41) from ($0.46) and lifting FY2026 to ($1.49) from ($1.73). These upgrades point to modestly improved expectations for near‑term results. MarketBeat TARA
• Neutral Sentiment: HC Wainwright retained a “Buy” rating and a $23.00 price target on TARA, which supports longer‑term upside potential if Protara meets clinical/corporate milestones. That endorsement may limit downside even as estimates were trimmed. MarketBeat TARA
• Negative Sentiment: HC Wainwright cut multiple 2026 quarterly and later‑year EPS forecasts (examples: Q1 to ($0.39) from ($0.33), Q2 to ($0.40) from ($0.34), Q3 to ($0.41) from ($0.35), Q4 to ($0.42) and FY2026 to ($1.61) from ($1.37); FY2027–FY2029 and FY2028 estimates were also reduced). Those downgrades signal increased expected cash burn or slower commercialization/progression assumptions and likely pressured the stock today. MarketBeat TARA

Institutional Trading of Protara Therapeutics

Several institutional investors have recently made changes to their positions in the company. Virtu Financial LLC acquired a new position in Protara Therapeutics in the fourth quarter valued at approximately $368,000. ADAR1 Capital Management LLC increased its stake in Protara Therapeutics by 3,127.4% during the fourth quarter. ADAR1 Capital Management LLC now owns 1,136,799 shares of the company’s stock worth $6,059,000 after acquiring an additional 1,101,576 shares during the last quarter. XTX Topco Ltd acquired a new stake in Protara Therapeutics during the fourth quarter worth $615,000. Sphera Funds Management LTD. purchased a new stake in Protara Therapeutics in the fourth quarter valued at $3,464,000. Finally, Quadrature Capital Ltd raised its position in Protara Therapeutics by 39.4% in the fourth quarter. Quadrature Capital Ltd now owns 24,184 shares of the company’s stock valued at $129,000 after purchasing an additional 6,838 shares during the period. Hedge funds and other institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.